The investigational cell therapy Descartes-08 led to durable reductions in disease severity for people with myasthenia gravis (MG), according to updated Phase 2b trial results presented by Cartesian Therapeutics, its developer. “Data reported today add to the growing body of evidence supporting the potential for Descartes-08 to provide…
The presence of antibodies targeting titin, a type of muscle protein, in patients with myasthenia gravis (MG) not associated with a thymus tumor is related to more frequent hospitalizations, according to a study in China. Frequent hospitalizations hurt quality of life and mental health for people with MG, and…
A man with a 16-year history of hard-to-treat generalized myasthenia gravis finally saw his disease successfully managed with Soliris (eculizumab) and then with Ultomiris (ravulizumab) — highlighting the efficacy of these newer treatments for myasthenia gravis (MG) — according to a new case study. Indeed, its author called…
Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with myasthenia gravis (MG), according to a study in China. Impending myasthenic crisis, or IMC, refers to symptoms rapidly worsening within a short time that may lead to a myasthenic crisis,…
The prefilled syringe used to administer Zilbrysq (zilucoplan) under the skin, or subcutaneously, can be safely and effectively used by generalized myasthenia gravis (gMG) patients, caregivers, and healthcare providers, a usability study in the U.S. shows. Most participants were able to use the syringe, which contained a placebo…
A maintenance regimen using an intravenous immunoglobulin (IVIG) therapy may reduce disease severity and improve function in people with generalized myasthenia gravis, according to data from a Phase 2 clinical trial. IVIG is commonly used to treat acute symptom worsening in people with myasthenia gravis (MG). The …
Long-term use of the immunosuppressant tacrolimus was found to be safe and effective in myasthenia gravis (MG) patients with self-reactive antibodies targeting muscle-specific kinase, or MuSK — a protein important in nerve-muscle communication — according to the findings of a new study by researchers in China. Treatment with tacrolimus significantly…
The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis (MG). The designation is given to medicines that aim to treat life-threatening or chronic debilitating conditions affecting no more than five in every 10,000 people. It provides companies with several…
Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized myasthenia gravis with anti-AChR antibodies, a real-world study in Italy shows. The treatment also reduced the number of disease exacerbations that required rescue therapy, such as intravenous immunoglobulin (IVIG)…
Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…
Get regular updates to your inbox.
